Department of the Navy April 3, 2017 – Federal Register Recent Federal Regulation Documents

The Department of the Navy hereby gives notice of its intent to grant to Epitracker, Inc. a revocable, nonassignable, exclusive license to practice the Government-Owned inventions described in the following U.S. Patent Applications: U.S. Patent Application No. 14/ 591660 (Navy Case No. 103395; U.S. Patent No. 9561206) titled ``Use of Heptadecanoic Acid (C17:0) to Detect Risk of and Treat Hyperferritinemia and Metabolic Syndrome''; U.S. Patent Application No. 14/980304 (Navy Case No. 103856) titled ``Heptadecanoic Acid Supplement to Human Diet''; U.S. Patent Application No. 14/980695 (Navy Case No. 103854) titled ``Method for Detecting Risk Factor for Metabolic Syndrome or Hyperferritinemia''; U.S. Patent Application No. 14/981130 (Navy Case No. 103855) titled ``Method for Treating Metabolic Syndrome''; U.S. Patent Application No. 15/030031 (Navy Case No. 105202) titled ``Compositions and methods for diagnosis and treatment of metabolic syndrome''; U.S. Patent Application No. 15/393771 (Navy Case No. 104602) titled ``Compositions and methods for diagnosis and treatment of anemia''; and U.S. Patent Application No. 15/393799 (Navy Case No. 105245) titled ``Compositions and methods for diagnosis and treatment of inflammation''; as well as any patent issuing thereon, any corresponding foreign patent applications and any foreign patent issuing thereon, and any re-issue, substitution, continuation (but not a continuation-in-part), or division thereof (to the extent that the inventions in the applications are claimed in the parent application on the effective date of the license.)